CN Patent
CN115322157B — 来特莫韦中间体化合物及其制备方法和应用
Assigned to Zhejiang Charioteer Pharmaceutical CO Ltd · Expires 2023-12-05 · 2y expired
What this patent protects
本发明公开了来特莫韦中间体化合物及其制备方法和应用。本发明具体公开了化合物II、III和IV,其结构如下所示。本发明提供了上述化合物在来特莫韦制备中的应用,具有操作简便、拆分效率高、收率更高、更适合工业化生产的优势。
USPTO Abstract
本发明公开了来特莫韦中间体化合物及其制备方法和应用。本发明具体公开了化合物II、III和IV,其结构如下所示。本发明提供了上述化合物在来特莫韦制备中的应用,具有操作简便、拆分效率高、收率更高、更适合工业化生产的优势。
Drugs covered by this patent
- Prevymis (LETERMOVIR) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.